Korea Exchange · Healthcare
JW stock from India: price, numbers and tax
JW (096760) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
JW at a glance
- Price
- ₩4,105.00-₩125.00 (2.96%)
- Market cap
- ₩284.03B
- Day range
- ₩4,105.00 – ₩4,260.00
- P/E
- 3.37
- Dividend yield
- 5.24%
- Volume
- 77.85K
- 1 month
- -2.38%
- 6 months
- -1.68%
- YTD
- +14.35%
- 1 year
- +27.68%
- 5 years
- +22.20%
JW statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩969.0B | ₩887.7B | ₩928.1B | ₩864.5B | ₩788.9B |
| Gross profit | ₩472.9B | ₩435.2B | ₩446.2B | ₩400.0B | ₩344.2B |
| Operating income | ₩163.7B | ₩146.5B | ₩143.7B | ₩110.7B | ₩62.1B |
| Net income | ₩58.5B | ₩62.6B | ₩19.0B | ₩22.2B | −₩2.8B |
| Earnings per share | ₩840.93 | ₩874.26 | ₩265.00 | ₩306.49 | −₩39.32 |
| EBITDA | ₩207.3B | ₩231.4B | ₩128.5B | ₩142.8B | ₩96.3B |
| Total assets | ₩1.2T | ₩1.3T | ₩1.2T | ₩1.2T | ₩1.1T |
| Total debt | ₩359.6B | ₩435.9B | ₩554.6B | ₩552.0B | ₩487.8B |
| Cash and short-term investments | ₩90.8B | ₩74.2B | ₩154.5B | ₩162.9B | ₩104.4B |
| Shareholders' equity | ₩267.0B | ₩229.5B | ₩124.0B | ₩107.0B | ₩93.2B |
| Operating cash flow | ₩163.7B | ₩97.9B | ₩112.3B | ₩104.4B | ₩109.6B |
| Free cash flow | ₩134.3B | ₩62.2B | ₩27.0B | ₩34.3B | ₩66.1B |
| Capital expenditure | −₩29.4B | −₩35.7B | −₩85.3B | −₩70.1B | −₩43.5B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| Samjin Pharmaceuticals | 005500.KS | ₩20,100.00 | ₩254.42B |
| AptaBio Therapeutics | 293780.KQ | ₩7,940.00 | ₩223.06B |
| REYON Pharmaceutical | 102460.KS | ₩10,280.00 | ₩188.55B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| JW Lifescience | 234080.KS | ₩10,940.00 | ₩169.40B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in JW from India
What JW does
JW Holdings Corporation, alongside its numerous subsidiaries, is a key player in the manufacturing and commercialization of pharmaceuticals and medical devices. Its operations span South Korea and global markets. JW operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell JW shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.